We designed a novel haploidentical hematopoietic stem cell transplantation (haplo-HSCT) system using idarubicin (IDA) intensified conditioning regimens and combination of antithymocyte globulin and basiliximab for GvHD prophylaxis. The outcomes of 110 high-risk acute leukemia patients undergoing haplo-HSCT were compared with 69 contemporaneous high-risk patients receiving HLA-matched sibling transplantation using uniform IDA-intensified regimens. The relapse incidence of haplo-HSCT was 23.4%, and 3-year overall survival (OS) and disease-free survival (DFS) achieved 62.9%, 59.1%, respectively. The cumulative incidences of Ⅱ-Ⅳ and Ⅲ-Ⅳ aGvHD were 28.6 and 14.3%, while limited and extensive cGvHD were 19.4, 13.8%. All these results were equivalent to those of concurrent identical sibling transplantation. Three-year OS and DFS for patients in advance stage reached 48.5, 47.3%. Furthermore, the relapse, 3-year OS of positive minimal residual disease (MRD) patients did not differ from negative MRD patients (18.9% vs 11.5%, 63.6% vs 69.6%), indicating our intensified haplo-HSCT technique could circumvent the dismal prognosis of MRD. These data provide reinforcing evidence that our haplo-HSCT system could dramatically improve the survival of high-risk acute leukemia with low relapse and acceptable transplantation-related mortality, and might be a promising therapeutic option for high-risk patients.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a major therapeutic modality for high-risk acute leukemia patients. Unfortunately, lack of a HLA-matched related or optimally matched unrelated donor often renders these patients ineligible for a potentially curative allograft. 1 With the advantages of widespread availability of donors, opportunity to select the best donor among family members to minimize treatment-related mortality (TRM), and improved treatability of post-transplant relapse, haploidentical HSCT (haplo-HSCT) has already become an attractive strategy for these high-risk patients. 1, 2 Relapse is the predominant factor influencing mortality of high-risk acute leukemia after allo-HSCT irrespective of which type donor transplantation. Some centers attempt to explore intensified conditioning regimens in HLA-matched HSCT to more efficiently eradicate residual leukemic cells and obtained impressive results. 3, 4 Our previous single-institute studies demonstrated that idarubicin-(IDA) intensified BUCY2 regimen could reduce relapse and improve survival for high-risk AML undergoing HLA-matched allo-HSCT, whereas IDA-intensified TBI-Cy regimen displayed excellent therapeutic effects for high-risk ALL patients. 5, 6 On the basis of these preliminary results, we speculated that IDA-intensified conditioning regimens could also help to improve the efficacy of haplo-HSCT in high-risk acute leukemia patients lacking a readily available HLA-matched donor.
Recent substantial progresses in HLA typing and GvHD prophylaxis techniques lead to markedly improved control of alloreactivity generated by major HLA-mismatched donors.
However, the incidence of GvHD after haplo-HSCT remains high, with the range around 38-63%. 1, [7] [8] [9] In vivo T-cell depletion with antithymocyte globulin (ATG), which induces vigorous immune tolerance, has been widely utilized in preventing the development of both aGvHD and cGvHD after haplo-HSCT. [10] [11] [12] Nevertheless, a high dose of ATG was accompanied by increased financial expenditure, poorer immune reconstitution and higher risk of lethal infections, whereas lower dose could not exert greatest control of GvHD. [13] [14] [15] [16] Basiliximab, a humanized anti-CD25mAb that blocks the IL-2Rα chain (CD25) to inhibit T lymphocyte activation, was previously indicated to significantly reduce GvHD incidence in unrelated donor transplantation. [17] [18] [19] ATG was reported to post-transcriptionally inhibit CD25, and ATG plus basiliximab treatment was found to significantly increase FoxP3 + Treg cells, 20 suggesting that these two agents have synergistic strong immunosuppressive effects. Besides, ATG has pleiotropic effects and a relatively prolonged half-life, whereas the function of basiliximab was short and selective. Thus, we hypothesized that low dosage of ATG incorporated with basiliximab may have synergism in mitigating GvHD without increasing severe infection and malignancy relapse. 20, 21 Hire et al. 22 attempted to utilize this combined protocol for islet allotransplant and achieved favorable result. G-CSF-primed bone marrow (BM) cells contain mesenchymal stem cells/mesenchymal (stromal) progenitor cells, which may possess immunoregulatory activity and allow the crossing of MHC barriers in donor-recipient. Thus, for fear of the appearance of increased non-relapse mortality and primary engraftment failure generated by the greater degree of HLA incompatibility in HLA3/6-matched setting, we adopted the combination of G-CSF-primed BM and PBSCs to facilitate hematopoietic and immune reconstitution and simultaneously elevated the total dose of ATG to 9 mg/kg to control GvHD. While in HLA4/6-matched transplant setting, we tried to explore lower dose of ATG coupled with basiliximab to avoid increased risk of relapse and infectious events, and simultaneously decrease expense related to ATG.
In the present study, in order to elucidate the efficacy and safety of our novel haplo-HSCT system for high-risk acute leukemia, we performed a contemporaneous comparative analysis of 110 haplo-HSCT using IDA-intensified regimens and stronger GvHD immunosuppressive prophylaxis of ATG and basiliximab with 69 patients receiving HLA-identical sibling transplantation adopting same IDA-intensified regimens. In addition, we carried out a preliminary evaluation of a suitable lower dose of ATG incorporated with basiliximab in our intensified haplo-HSCT system.
PATIENTS AND METHODS Patients
Clinical data of 179 consecutive patients with high-risk acute leukemia who received allo-HSCT between March 2011 and November 2015 at the Union Hospital of Huazhong University of Science and Technology were retrospectively analyzed. We classified patients as high risk at diagnosis following the criteria in our previous reports. 5, 6, 23 Patients were assigned to haplo-HSCT (n = 110) or HLA-identical sibling transplantation (n = 69) according to donor availability. Patient was eligible for haplo-HSCT if a matched sibling donor or suitable closely HLA-matched unrelated donor was unavailable or if there was insufficient time for an unrelated donor search due to disease status. The number of patients transplanted with 3/6 vs 4/6 haplo donors were 62 and 48, respectively. Patients receiving haplo-HSCT followed the treatment diagram shown in Figure 1 , and patients undergoing HLA-identical sibling transplantation were treated as in our previous reports. 5, 6, 23 All enrolled individuals were observed longitudinally until death or lost to follow-up. Inadequate organ function as defined by bilirubin >2.5 mg/dL, creatinine >2 mg/dL, cardiac ejection fraction <45%, forced expiratory volume in 1 s and forced vital capacity <60% predicted, Karnofsky performance status <70% was exclusion criteria of our study. The study protocol was approved by the Institutional Review Board on Medical Ethics at Huazhong University of Science and Technology. All patients and donors or their legal guardians provided signed informed consent in accordance with the Declaration of Helsinki.
HLA matching
All donor/recipient pairs were typed at HLA-A, B and -DR loci at our institute. HLA-A and HLA-B typing was performed by intermediateresolution DNA typing, whereas HLA-DRB1 typing was performed using high-resolution DNA techniques. Haplo-HSCT recipient received stem cells from a family member who was identical at one HLA haplotype with the patient but differed to a variable degree for the HLA-A, B and DR antigens of the unshared haplotype. Donors were preferentially ranked according to HLA-matched loci, younger age, male sex and better performance status.
Stem cell source
Donor BM stem cells and/or PBSCs were collected using standard mobilization protocols. All donors were primed with recombinant human granulocyte (rhG-CSF) 8-10 μg/kg per day injected subcutaneously to mobilize BM and/or peripheral blood. For HLA-identical sibling and HLA4/6-matched transplantation, unmanipulated G-CSF-primed PBSCs were infused into the recipient on the day of collection. For the donor-recipient HLA3/6-matched setting, both G-CSF-primed BM (harvested on day 0, 4 days after G-CSF) and G-CSF-primed PBSCs (harvested on day 1-2, 5-6 days after G-CSF) were harvested and infused into the recipients on the day of collection without manipulation.
Conditioning regimens
In accordance with our previous studies, 5, 6, 23 high-risk AML patients received IDA-intensified modified BUCY2 regimen that included IDA (15 mg/m 2 per day IV, for more than 20 h, days − 11 to − 9), oral hydroxycarbamide (80 mg/kg on day − 9), i.v. injection of cytarabine (2 g/m 2 on day − 8), followed by i.v. injection of BU (3.2 mg/kg in divided doses daily, on days − 7 to − 5), CY (1.8 g/m 2 on days − 4 to − 3) and oral Me-CCNU (250 mg/m 2 on day − 2). High-risk ALL patients received IDA-intensified TBI-Cy regimen that included TBI (8 Gy in a single fraction) with partial shielding of the lungs on day − 8, IDA (15 mg/m 2 per day IV, for more than 20 h, days − 6 to − 5) and Cy (60 mg/kg/ per day IV, days − 3 to − 2). For donor-recipient HLA4/6-matched setting, patients additionally received ATG (Thymoglobulin, Sanofi Aventis, Paris, France) at a total dose of 6 mg/kg (3 mg/kg per day, days − 1 to 0). For HLA3/6-matched transplant, a total dose of 9 mg/kg ATG (3 mg/kg per day, days − 4 to − 2) was used.
GvHD prophylaxis
For HLA-identical sibling transplantation, patients received a GvHD prophylaxis regimen consisting of cyclosporine A (CsA) and short-term methotrexate (MTX). A combination of CsA, short-term MTX, mycophenolate mofetil and basiliximab was provided to haplo-HSCT recipients as GvHD prophylaxis. CsA 2.5 mg/kg per day was given as a continuous IV infusion from day 1 until patients were able to tolerate oral medication. Individualized dosage adjustment of CsA was based on plasma concentration to maintain a target dose of 150-250 ng/mL. CsA was progressively Intensified haplo-vs ISD-HSCT for high-risk ALtapered by 5% weekly and discontinued after around 3-4 months in cases with no evidence of GvHD. MTX was administered intravenously at dosages of 15 mg/m 2 on day +1 and 10 mg/m 2 on days +3, +6 and +11. Mycophenolate mofetil (7.5 mg/kg, orally twice daily) was administered from day − 9, which was tapered to half until day +60 and was discontinued thereafter based on the presence or absence of severe GvHD, infectious diseases and relapse risk. Basiliximab was given intravenously at a dose of 20 mg by 30-minute IV infusion on day 0 (2 h before graft infusion) and day +4. Diagnosis and clinical grading of aGvHD and cGvHD were established according to the standard criteria. 24, 25 Hematopoietic reconstitution and transplantation-related toxicity
The evaluation of hematopoietic reconstitution was similar to that reported previously. 5, 6, 23 Transplantation-related toxicity was evaluated by common criteria set by the National Cancer Institute (NCIC).
Supportive care
Antimicrobial prophylaxis was performed as previously reported. 5, 6, 23 Biweekly CMV monitoring by PCR was started on day − 7, until day +100 and weekly until day +180, followed by once every month until 1 year after HSCT. Ganciclovir or foscarnet was initiated with evidence of CMV reactivation defined as a CMV DNA viral load more than 500 copies per mL by PCR at any time after HSCT until the CMV DNA monitoring was negative on two occasions.
Statistical analyses
Demographic characteristics were compared between cohorts using χ 2 and Fisher's exact tests for categorical variables, and Mann-Whitney U-test for continuous variables. Rates of hematopoietic recovery, GvHD, relapse and TRM were calculated using cumulative incidences, taking into account competing risks. Relapse and TRM were considered to be mutually competing risks. When calculating neutrophil, platelet recovery and GvHD, the competing risk was death. Overall survival (OS) and disease-free survival (DFS) were estimated by using the Kaplan-Meier method and the curves of various subgroups were compared by the log-rank tests. Using the stepwise selection procedure for all of the variables of interest, the Cox proportional hazards model was used for multivariate analyses of relapse, OS and DFS. All P-values are two sided, and a P-value of <0.05 was considered significant. SPSS 17.0 statistical software (SPSS Inc., Chicago, IL, USA) was used and graphs were drawn with Graphpad Prism 5.0 (Graphpad software, Inc., San Diego, CA, USA).
RESULTS

Patient and donor characteristics
Detailed information regarding patient, disease and transplant characteristics of two groups was summarized in Table 1 . The median follow-up for all patients was 20 months (range, 0.5-68), whereas for the survivors was 28 months (range, 12-68). There was no significant difference between haplo-HSCT and HLA-identical sibling HSCT with regard to basic characteristics. Hematopoietic recovery Only one patient in each group died of pulmonary infection, the remaining achieved hematopoietic recovery after transplantation. Analysis of chimerism indicated that all patients surviving beyond day +28 after HSCT achieved full-donor chimerism by day +30. Time-to-engraftment of neutrophils was significantly faster in patients receiving identical sibling HSCT than in haplo-HSCT (11.5 vs 13 days, P = 0.031) (Supplementary Figure S1a) . However, time-to-engraftment of platelets did not differ between patients receiving haplo-HSCT and identical sibling HSCT (14 vs 14 days, P = 0.167) (Supplementary Figure S1b) . In haplo-HSCT group, the median myeloid engraftment time was 12 and 14 days in HLA3/6-and HLA4/6-matched settings (P = 0.018) (Supplementary Figure S2a) . The median platelet engraftment was comparable between HLA3/6-and HLA4/6-matched groups (13 vs 15 days, P = 0.408) (Supplementary Figure S2b) .
Toxicity of conditioning regimens
No lethal regimen-related toxicity occurred in two groups. The most commonly observed toxicities involved gastrointestinal tract, including mild nausea/vomiting (41.8% vs 36.2%, P = 0.457) and diarrhea (21.8% vs 29.0%, P = 0.278). Febrile episodes were also common during the neutropenic period (65.5% vs 59.4%, P = 0.415). Oropharyngeal mucositis was more often observed in our IDA-intensified conditioning regimen. For IDA-intensified haplo-HSCT, 73 cases (66.4%) of oropharyngeal mucositis (60.9% Abbreviations: allo-HSCT = allogeneic hematopoietic stem cell transplantation; CR1 = the first CR; CR2 = the second CR; CR3 = the third CR; NR = non-CR.
Intensified haplo-vs ISD-HSCT for high-risk AL R Zhang et al grade Ⅰ-Ⅱ and 5.5% grade Ⅲ) was observed. For IDA-intensified identical sibling transplantation, 43 cases (62.3%) of oropharyngeal mucositis (58.0% grade Ⅰ-Ⅱ and 4.3% grade Ⅲ) was observed. Reversible elevations of liver enzymes were commonly seen in two groups (53.6% vs 47.8%, P = 0.449). However, only one patient with high-risk AML receiving identical sibling transplantation suffered mild hepatic veno-occlusive disease (HVOD) and was cured by therapy. Reversible elevations of creatinine and/or urea nitrogen were also often observed in two groups (43.6% vs 37.7%, P = 0.431). Despite the use of IDA in our IDA-intensified regimen, no cardiotoxicity was recorded except that four cases in haplo-HSCT and two in identical sibling HSCT had grade I-II hypertension. Pulmonary toxicity and transplantrelated thrombotic microangiopathy were not observed in the two groups. About 98 patients in haplo-HSCT and 64 patients in identical sibling HSCT who survived longer than 100 days post transplant were eligible to be evaluated for cGvHD. As shown in Supplementary Figure S1d , the cumulative incidences of cGvHD after haplo-HSCT and identical sibling HSCT were 32.6%, 30.3%, respectively (HR, 1.170; 95% CI: 0.620-2.208, P = 0.629). There were no significant differences with regard to the incidences of limited and extensive cGvHD in haplo-HSCT and identical sibling HSCT For the haplo-HSCT, the cumulative incidences of aGvHD or cGvHD did not vary in HLA3/6-and HLA4/6-matched settings (Supplementary Figures S2c,d ).
GvHD incidence and severity
Relapse For the whole of 110 patients receiving haplo-HSCT, 19 patients experienced relapse after a median time of 6.5 months (range, 2-17) after transplantation. Among all cases of relapse, 14 experienced hematological relapse, 3 experienced cytogenetic relapse, while 2 experienced relapse at other extramedullary sites. Among 69 patients undergoing identical sibling transplantation, relapse occurred in 15 patients at a median time of 8.5 months (range, 1.5-18) post transplant, including 8 hematological relapse, 4 cytogenetic relapse and 3 relapse at other extramedullary sites.
The 3-year estimated cumulative incidences of relapse were not significantly different between haplo-HSCT and identical sibling HSCT (23.4% vs 28.3%; HR, 0.905; 95% CI: 0.464-1.764, P = 0.769) (Figure 2a) . For AML patients, the relapse rates between haplo-HSCT and identical sibling HSCT were 19.9%, 24.8% (HR, 1.113; 95% CI: 0.407-3.045, P = 0.834). While for ALL patients, the relapse rates were 26.2% and 29.2% in the two groups, respectively (HR, 0.805; 95% CI: 0.316-2.054, P = 0.650) (Figure 3a) .
After haplo-HSCT, the cumulative incidences of relapse did not differ between HLA3/6-and HLA4/6-matched settings in either high-risk AML or ALL patients (Supplementary Figure S3a) . Infections Eighty-three (75.5%) patients were diagnosed with CMV reactivation and received pre-emptive anti-CMV therapy in haplo-HSCT group. The median time of CMV reactivation was 35 days (range, 15-161) post transplant. However, in identical sibling transplantation, the incidence of CMV reactivation Intensified haplo-vs ISD-HSCT for high-risk ALwas 46.4% in 32 patients at 32 days (range, 20-157) post transplantation. There was a remarkable difference between the two groups in terms of CMV reactivation (P o 0.001). No cases of fatal CMV disease occurred during the follow-up period owing to intensive surveillance and pre-emptive antiviral therapy. The proportion of patients with bacterial infections was not significantly different in the two groups (35.5% vs 40.6%, P = 0.490). Furthermore, in the setting of haplo-HSCT, the incidence of CMV reactivation in HLA3/6 was 77.4%, which was not different from that in HLA4/6 of 72.9% (P = 0.586). However, patients in HLA3/6 had 199 episodes of CMV reactivation during the study period, with a mean of 3.2 (0-8) episodes per patient, which was significantly higher than in HLA4/6 of 98 episodes, with a mean of 2.0 (0-6) episodes (P = 0.017).
TRM and causes of death
No deaths resulted from lethal organ toxicity during the 40 days after HSCT. About 23 patients (20.9%) in haplo-HSCT and 13 (18.8%) in identical sibling transplantation, respectively, died from transplantation-related complications. The 3-year estimated cumulative incidence of TRM was not significantly different between haplo-HSCT and identical sibling HSCT (23.2% vs 24.2%; HR, 1.308; 95% CI: 0.673-2.545, P = 0.428) (Figure 2b) .
As shown in Figure 3b , for AML patients, the TRM in haplo-HSCT and identical sibling transplantation were 20.4, 25.2% (HR, 1.140; 95% CI: 0.452-2.873, P = 0.781). While for ALL patients, the TRM in the two groups was 26.6% and 23.2%, respectively (HR, 1.538; 95% CI: 0.589-4.017, P = 0.290). Variables, including age, sex, disease status, interval from diagnosis to transplantation, donor-recipient relationship and infused nucleated and CD34 + cell dose were not significantly predictive of TRM.
In the context of haplo-HSCT, the cumulative incidences of TRM did not differ between HLA3/6-and HLA4/6-matched settings in either high-risk AML or ALL patients (Supplementary Figure S3b) .
The causes of death in the two groups are shown in Supplementary Table S1. OS and DFS After a median follow-up of 28.0 months (range, 12-68) for survivors, the 3-year probabilities of OS and DFS for haplo-HSCT and identical sibling transplantation were 62.9% (95% CI: 38.93-50.67%) vs 61.9% (95% CI: 39.26-53.21%), 59.1% (95% CI: 36.68-48.54%) vs 58.0% (95% CI: 36.20-50.88%), respectively (Figures 2c,d) . The 3-year OS and DFS were not significantly different between the two groups (HR, 1.197; 95% CI: 0.722-1.985; P = 0.486; HR, 1.166; 95% CI: 0.717-1.893; P = 0.536).
As shown in Figures 3c,d , 3-year OS and DFS for high-risk AML patients were not significantly different between haplo-HSCT and identical sibling transplantation (OS: 66.5% vs 64.5%, P = 0.629; DFS: 63.3% vs 60.0%, P = 0.656). There were no significant differences with regard to 3-year OS and DFS for high-risk ALL patients between the two groups (OS: 58.5% vs 59.0%, P = 0.583; DFS: 54.0% vs 55.8%, P = 0.632).
In addition, after haplo-HSCT, the cumulative incidences of OS and DFS were not different between HLA3/6 and HLA4/6 matching transplant in either high-risk AML or ALL patients (Supplementary Figures 3c,d) . Table 2 , multivariate analysis failed to show significant differences in relapse, OS and DFS between haplo-HSCT and identical sibling transplantation. The disease type did not significantly affect relapse, OS and DFS. Patients with Intensified haplo-vs ISD-HSCT for high-risk AL R Zhang et al limited cGvHD experienced a significantly better OS and DFS than those without cGvHD or those with extensive cGvHD (P = 0.037, P = 0.025). Patients who developed Ⅲ-Ⅳ aGvHD had worse OS and DFS (P = 0.026, P = 0.045). Other factors had no association with relapse, OS and DFS. Non-CR (NR) status before allo-HSCT was significant prognostic factor of increased relapse (P = 0.005), which was associated with a lower OS and DFS (P = 0.013, P<0.0001).
Multivariate analysis As shown in
CR MRD(− ) vs CR MRD(+) vs NR
In the haplo-HSCT setting, we further divided CR patients into minimal residual disease (MRD)( − ) and MRD(+) according to the status of molecular remission pre-HSCT. The number of patients in CR MRD( − ), CR MRD(+), NR was 59, 22, 29. As shown in Figure 4a , the cumulative incidence of relapse for CR MRD( − ), CR MRD(+), NR patients were 11.5, 18.9, 47.1. The relapse incidence for NR patients was significantly higher when compared with CR MRD( − ) (P = 0.0001) and CR MRD(+) patients (P = 0.045). The 3-year OS for CR MRD( − ), CR MRD(+), NR patients were 69.6, 63.6, 48.5% (Figure 4b ). There was no significant difference between CR MRD ( − ) and CR MRD(+), whereas the 3-year OS for NR patients was remarkably lower than CR MRD( − ) patients (P = 0.033). The 3-year DFS for CR MRD( − ), CR MRD(+), NR patients were 69.0, 63.6, 47.3% (Figure 4c ). The 3-year DFS for NR patients was dramatically lower than CR MRD( − ) patients (P = 0.020).
DISCUSSION
In the present study, we first demonstrated that for high-risk acute leukemia patients who do not have suitable HLA-matched donors and in need of urgent transplantation, IDA-intensified conditioning haplo-HSCT with combined GvHD prophylaxis of ATG and basiliximab could achieve satisfactory results of 3-year OS 62.9%, low relapse rate and acceptable TRM, which was comparable with HLA-identical sibling transplantation. Remarkably, for MRD-positive patients, our intensified haplo-HSCT system resulted in equivalent therapeutic effect as for MRD-negative patients. Recently, the prognosis of high-risk acute leukemia after haplo-HSCT was still disappointing. 26 McCurdy et al. 27 reported that 3-year OS and DFS were 35, 22% for high-risk hematologic patients receiving non-myeloablative haplo-HSCT with PT-Cy.
Di Bartolomeo et al. 21 adopted haploidentical BM transplantation following myeloablative or reduced preparative regimen for high-risk acute leukemia patients and 3-year OS was~45%. Encouragingly, by using IDA-intensified haplo-HSCT with GvHD prophylaxis of ATG and basiliximab herein, the 3-year OS and DFS for high-risk patients was as high as 62.9% and 59.1%, respectively, which was almost consistent with the outcomes of our contemporaneous HLA-matched identical sibling transplants. It is noteworthy that in our study, the 3-year OS and DFS for haplo-HSCT patients in active disease reached 48.5, 47.3%. Whereas the results from EBMT and other researchers showed that 2-year DFS for acute leukemia patients in advanced stage undergoing haplo-HSCT was only 1-37%, 28, 29 suggesting that our novel haplo-HSCT system is highly effective for advanced acute leukemia.
Although some studies suggested that haplo-HSCT may be associated with a profound GvL effect, 30 ,31 the relapse after haplo-HSCT currently was only comparable or slightly lower than HLA-matched HSCT, with cumulative incidence for high-risk hematologic patients still up to 45-69%. [32] [33] [34] For this reason, we adopted IDA-intensified conditioning schemes in haplo-HSCT for high-risk acute leukemia and obtained prominently low incidence of relapse (23.4%), which was comparable with identical sibling transplantation using uniform intensified regimens and significantly lower than those using traditional BUCY2 or TBI-Cy regimens (39.0-52.9%) in our previous studies. 5, 6, 23 It was reported that 1-year and 3-year cumulative incidences of relapse were 58, 67% for high-risk hematological patients receiving non-myeloablative haplo-HSCT. 27 Solomon et al. 35 indicated that for high-risk acute leukemia patients undergoing TBI-based myeloablative haplo-HSCT, the relapse rate at 2-year was 53%. Thus, we can speculate that low relapse preponderance in our study was mostly attributed to high intensity of conditioning regimen rather than GvL effects produced by HLA disparity and our intensified haplo-HSCT was a valid option to reduce relapse for high-risk acute leukemia.
It has been reported that the risk of relapse was strongly correlated with the level of MRD in BM immediately before allo-HSCT. 36 The patients with MRD positivity at the time of transplantation had significantly higher rates of progression and inferior survival compared with those of MRD negativity. 37, 38 Deeper control of leukemia pre-transplant has a crucial function in preventing relapse post transplant in high-risk acute leukemia. 36 In the present cohort, the relapse and survival post transplant of positive MRD patients were nearly comparable to negative MRD patients. Therefore, it suggested that our novel intensified haplo-HSCT protocol could surmount the poor prognosis generated by MRD positivity at transplant. As for some high-risk refractory MRD-positive patients who are hard to enter MRD negativity and potentially possess the risk of progressing to overt hematologic relapse after continuous chemotherapies, the time of transplantation might move forward to hematologic CR without chasing negative MRD in our IDA-intensified haplo-HSCT system.
In the past decade, significant progress has been made to overcome the challenging barriers in haplo-HSCT through diverse GvHD prevention strategies, nevertheless, GvHD remains a frequent life-threatening complication after haplo-HSCT. Recently, Baker et al. 8 and Raj et al. 39 consistently reported high cumulative incidences of Ⅱ-Ⅳ caGvHD of 63 and 53% in patients receiving haplo-HSCT using PT-Cy as GvHD prophylaxis. The GIAC protocol, pioneered in China, comprised ATG for GvHD prophylaxis, however, the incidence of Ⅱ-Ⅳ haGvHD was reported to be 36.3-42.0% and cGvHD was 54.9-65.5%. 31, 40 Inspiringly, the cumulative incidences of Ⅱ-Ⅳ and Ⅲ-Ⅳ aaGvHD in haplo-HSCT of our present research were 28.6% and 14.3%, respectively. The cumulative incidences of limited and extensive cGvHD were 19.4, 13.8%. Both aGvHD and cGvHD were comparable with the rates of identical sibling transplantation in homochronous study. Thus, our Abbreviations: aGvHD = acute GvHD; ALL = acute lymphocytic leukemia; cGvHD = chronic GvHD; CI = cumulative incidence; CR = complete remission; DFS = disease-free survival; haplo-HSCT = haploidentical hematopoietic stem cell transplantation; HR = hazard ratio; HSCT = hematopoietic stem cell transplantation; NR = non-CR; OS = overall survival.
Intensified haplo-vs ISD-HSCT for high-risk ALresults confirmed the distinct superiority of ATG incorporated with basiliximab for preventing GvHD in haplo-HSCT. An Italian group also tried to combine ATG with basiliximab as GvHD prophylaxis strategy and succeeded in reducing cGvHD to 17%. 21 However, the TRM therein was as high as 36% because of high proportion of fatal infection before myeloid recovery, which may be ascribed to G-CSF-primed BM as only graft composition used in their study that lead to delayed hematopoietic and immune reconstitution. All these results indicate that ATG plus basiliximab treatment might be a promising and strong immunosuppressive therapy but preferred for haplo-HSCT using G-CSF-primed PBSCs platform that may acquire faster hematopoietic recovery.
To the best of our knowledge, in vivo T-cell depletion with highdose ATG delays T-cell immune reconstitution and poses heightened risk of severe infections, including CMV, bacterial infection, as well as infection-related deaths. 41 The incidence of CMV reactivation was 75.5% in our study, which was significantly higher than in contemporaneous identical sibling transplant but was comparable with GIAC protocol (75.5-78.6%). 13 Basiliximab binds specifically to the IL-2R of activated T cells with high affinity and only selectively depletes the alloreactive donor lymphocytes, without affecting the resting T cells and other additional cellular components, 42 which may account for similar incidences of CMV reactivation in our haplo-HSCT scheme employing ATG plus basiliximab and GIAC protocol using only ATG for preventing GvHD. Thus, we could induce that ATG combined with basiliximab was complementary integration without increasing CMV infection.
In our haplo-HSCT system, we made an initial attempt to adopt different ATG dosage and infused composition according to different donor-recipient HLA matching circumstances. We tried to reduce the dose of ATG to 6 mg/kg and use only G-CSF-primed PBSCs in HLA4/6 matching transplant, while in HLA3/6 transplant we still adopt G-CSF-primed BM plus PBSCs and 9 mg/kg ATG to prevent GvHD. Intriguingly, our results of HLA4/6 were comparable to HLA3/6 transplant, including resemble incidence of GvHD, relapse rate and survival. Although the frequency of CMV reactivation did not fall in HLA4/6 matching transplant, the episode of reactivation was remarkably decreased. Therefore, it could be inferred that the application of G-CSF-primed PBSCs and 6 mg/kg ATG system might be broadened to HLA3/6-matched haplo-HSCT in near future. Nevertheless, further investigation in prospective randomized studies is warranted to draw firm conclusions.
In summary, our IDA-intensified haplo-HSCT with GvHD prophylaxis of ATG with basiliximab could improve the outcome of high-risk acute leukemia as intensified identical sibling transplantation and represents a valid option for high-risk acute leukemia patients. More detailed analyses are under way to get information on immune reconstitution and other virus infections in this original haplo-HSCT circumstance. 
